文献速递乳腺技术与安全PETSPECT

核医学检查中偶然发现的乳腺病变的管理

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations.
PubMed 文献 · Radiol Imaging Cancer · 2020-03-20

本文综述了在平面、SPECT和PET核医学检查中偶然发现的乳腺良恶性病变的分子与影像学表现,涉及sestamibi、骨扫描、放射性碘及多种PET示踪剂(18F-FDG、68Ga-DOTATATE、68Ga-PSMA、18F-fluciclovine)。在分子和解剖影像上识别这些病变对于确保准确诊断和适当管理很重要。

要点

  • 核医学检查中乳腺偶然摄取可见于非乳腺癌患者,需鉴别良恶性。
  • 识别平面、SPECT和PET上的乳腺病变表现有助于准确诊断。
  • 多种示踪剂(如FDG、DOTATATE、PSMA)均可显示乳腺病变。

核心结论

  • 在分子和解剖影像上识别乳腺偶然摄取病变对确保准确诊断和适当管理很重要。

研究设计与样本

  • 综述,总结了sestamibi扫描、骨扫描、放射性碘研究以及使用18F-FDG、68Ga-DOTATATE、68Ga-PSMA和18F-fluciclovine PET示踪剂的乳腺病变影像表现。

关键影像表现/征象

  • 良恶性乳腺病变可在平面、SPECT和PET扫描上被识别。
  • 综述概述了上述多种核医学检查中乳腺良恶性病变的分子和影像学表现。

临床应用与阅片要点

  • 在平面、SPECT和PET图像上识别乳腺偶然摄取,结合分子和解剖影像特征,以助准确诊断和适当管理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the molecular and radiographic imaging appearance of benign and malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluorine 18 (18F) fluorodeoxyglucose, gallium 68 (68Ga) tetraazacyclododecane tetraacetic acid octreotate (or DOTATATE), 68Ga prostate-specific membrane antigen, and 18F-fluciclovine radiotracers. Recognizing these lesions at molecular and anatomic imaging is important to ensure accurate diagnosis and appropriate management. Keywords: Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT © RSNA, 2020.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Rahman WT, Neal CH, Nees AV, et al. Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations. Radiol Imaging Cancer. 2020. PMID: 33778704. doi:10.1148/rycan.2020190037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。